These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28564576)

  • 1. The endocannabinoid system as a target for addiction treatment: Trials and tribulations.
    Sloan ME; Gowin JL; Ramchandani VA; Hurd YL; Le Foll B
    Neuropharmacology; 2017 Sep; 124():73-83. PubMed ID: 28564576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
    Galaj E; Xi ZX
    CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the endocannabinoid system in drug addiction.
    Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
    Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions
.
    Spanagel R
    Dialogues Clin Neurosci; 2020 Sep; 22(3):241-250. PubMed ID: 33162767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of the endocannabinoid system in drug addiction.
    Maldonado R; Valverde O; Berrendero F
    Trends Neurosci; 2006 Apr; 29(4):225-32. PubMed ID: 16483675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
    Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
    JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation.
    Butler K; Le Foll B
    Expert Opin Drug Discov; 2020 Sep; 15(9):1065-1080. PubMed ID: 32425077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoids and striatal function: implications for addiction-related behaviours.
    Moreira FA; Jupp B; Belin D; Dalley JW
    Behav Pharmacol; 2015 Feb; 26(1-2):59-72. PubMed ID: 25369747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the endogenous cannabinoid system in drug addiction.
    Parolaro D; Rubino T
    Drug News Perspect; 2008 Apr; 21(3):149-57. PubMed ID: 18560613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The endocannabinoid system: emotion, learning and addiction.
    Moreira FA; Lutz B
    Addict Biol; 2008 Jun; 13(2):196-212. PubMed ID: 18422832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis and psychiatric disorders: it is not only addiction.
    Leweke FM; Koethe D
    Addict Biol; 2008 Jun; 13(2):264-75. PubMed ID: 18482435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurobiology and systems physiology of the endocannabinoid system.
    Wegener N; Koch M
    Pharmacopsychiatry; 2009 May; 42 Suppl 1():S79-86. PubMed ID: 19434559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.
    Le Foll B; Goldberg SR
    J Pharmacol Exp Ther; 2005 Mar; 312(3):875-83. PubMed ID: 15525797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder.
    Martin EL; McRae-Clark AL
    Curr Addict Rep; 2020 Dec; 7():545-552. PubMed ID: 33816054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.
    Sloan ME; Grant CW; Gowin JL; Ramchandani VA; Le Foll B
    Acta Pharmacol Sin; 2019 Mar; 40(3):342-350. PubMed ID: 30166624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking and Addiction.
    Peters KZ; Oleson EB; Cheer JF
    Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 31964646
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.
    Soler-Cedeno O; Xi ZX
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.